Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebiome for Depression in Lebanese Population
NCT05646784Phase 4Completed
- Sponsor
- Saint Joseph's University
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Multi-strain Products
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Cerebiome in major depressive disorder (MDD) (3 arms), sponsored by Saint Joseph's University. Primary endpoint: Concentration of plasma inflammatory markers at 12 weeks. Started Jan 2024; status: completed.
02
Drugs
Cerebiome
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05646784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05646784.